Epigral Ltd

Q1 FY27, unaudited

Revenue: ₹705.36 Cr
Profit after tax: ₹99.74 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ crore	Q1 FY27	vs a year ago	FY26
Revenue from operations	705.36	+16.29%	2,527.18
Other income	4.10	−50.30%	14.98
Total income	709.46	+15.40%	2,542.16
Employee benefit expense	36.70	+22.17%	129.66
Finance costs	7.22	−69.11%	71.96
Depreciation & amortisation	42.90	+3.27%	168.29
Total expenses	576.28	+13.43%	2,200.36
Profit before tax	133.18	+24.78%	341.80
Tax expense	34.00	+163.34%	8.79
Profit after tax	99.74	−37.93%	331.97
Total comprehensive income	99.75	−37.88%	332.00

Earnings per share
Earnings per share, basic	₹23.12	₹76.95
Earnings per share, diluted	₹23.12	₹76.95

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Earnings call

Q1 FY27

Epigral reported Q1 FY27 revenue growth of 15% to Rs 709 crore and EBITDA margin of 25%, aided by higher sales volumes and improved realizations despite disruptions from the West Asia conflict affecting shipping and raw material costs. The Board approved capex for two new projects, a 125,000 tonnes per annum Epoxy Resin and Formulations facility and a multipurpose plant for chlorotoluene and epichlorohydrin derivatives, both targeted to have pilot facilities operational by Q2 FY27. Management discussed capacity utilization across segments, ECU and ECH realizations, and the rationale for backward integration and export strategy for the new capacities.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 53 published by the exchange

18 Aug 2026
Concall
Analyst / Investor Meet - Intimation
07 Aug 2026
Concall
Analyst / Investor Meet - Intimation
30 Jul 2026
Concall
Analyst / Investor Meet - Intimation
30 Jul 2026
Transcript
Earnings Call Transcript
29 Jul 2026
Filing
Newspaper Publication
Appears 2 times in the recent filings shown; listed once.
27 Jul 2026
Concall
Analyst / Investor Meet - Outcome
27 Jul 2026
Presentation
Investor Presentation
27 Jul 2026
Filing
Press Release / Media Release
27 Jul 2026
Board meeting
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') - Outcome Of Board Meeting
27 Jul 2026
Board meeting
Board Meeting Outcome for Outcome Of Board Meeting Held On Monday, 27Th July, 2026 And Submission Of Un-Audited Financial Results (Standalone & Consolidated) For The First Quarter Ended 30Th June, 2026.
27 Jul 2026
Results
UNAUDITED FINANCIAL RESULTS - 30.06.2026
22 Jul 2026
Filing
Epigral Limited''s Reply To Clarification Sought With Reference To Movement In Volume.

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 18 Aug 2026.